CING · CIK 0001862150 · FY2025 live · 2025-12-31
Cingulate Inc.
View as
Model
Classic Z
FY2025
−16.41
Zone
Distress
Prior
—
Market DD
—
1y PD
—
−16.41
Z″ −36.57
Score −16.41 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.111.2 × = 0.13X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−8.781.4 × = −12.29X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
−1.323.3 × = −4.37X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
0.200.6 × = 0.12X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.001 × = 0.00
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings.
Meridian Rank
4.82
0–100 · Classic Z family
Book standing
4
Year change
—
Market PD
—
O-score
7
Events on this name
Same published rows as Today.
No published events on this print.
Overview
rule-v1
Cingulate Inc. is on classic Z at −16.41 (distress) for FY2025, from an SEC 10-K. Retained earnings / assets is the line that sets the print. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers. Buybacks can send retained earnings negative at otherwise healthy issuers. X4 is book equity.
Book screen Distress; market PD —. Market PD has not been priced on this name.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 8th percentile in Healthcare.
- VERUDistressVERU INC.−16.22
- VTGNDistressVistagen Therapeutics, Inc.−16.18
- ELTXDistressElicio Therapeutics, Inc.−16.90
- STXSDistressStereotaxis, Inc.−15.90
- PPCBDistressPropanc Biopharma, Inc.−16.96
- AGPUDistressAxe Compute Inc.−15.82
- FTHDistressFaeth Therapeutics, Inc.−17.03
- SCNIDistressScinai Immunotherapeutics Ltd.−15.75
Filing line items
Current assets
$12M
Total assets
$15M
Current liabilities
$10M
Total liabilities
$13M
Working capital
$2M
Retained earnings
−$132M
EBIT
−$20M
Total sales
$0
Book equity
$3M
Accession 0001493152-26-010882. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as is a display overlay. X4 is book equity. Pulled 13 Sept 2026.